{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:15:48Z","timestamp":1791807348112,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.rdc.2014.12.005","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T16:45:11Z","timestamp":1424969111000},"page":"237-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Interstitial Lung Disease in Scleroderma"],"prefix":"10.1016","volume":"41","author":[{"given":"Sara R.","family":"Schoenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia V.","family":"Castelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1148\/radiology.176.3.2389033","article-title":"Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography","volume":"176","author":"Churawitzki","year":"1990","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.rdc.2014.12.005_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.1780280706","article-title":"Pulmonary involvement in systemic sclerosis (scleroderma)","volume":"28","author":"Steen","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2014.12.005_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2014.12.005_bib4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"McNearney","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2014.12.005_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib7","first-page":"429","article-title":"Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis","volume":"21","author":"Yanaba","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib8","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"3 Pt 1","key":"10.1016\/j.rdc.2014.12.005_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1164\/ajrccm\/144.3_Pt_1.706","article-title":"Structural features of interstitial lung disease in systemic sclerosis","volume":"144","author":"Harrison","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/187152812800959013","article-title":"Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy","volume":"11","author":"Jain","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1165\/ajrcmb.10.4.7510986","article-title":"Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor","volume":"10","author":"Ohba","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","article-title":"Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease","volume":"63","author":"Bogatkevich","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11926-014-0411-1","article-title":"Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease","volume":"16","author":"Akter","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2014.12.005_bib14","first-page":"69","article-title":"Transforming growth factor-beta: a key mediator of fibrosis","volume":"117","author":"Mauviel","year":"2005","journal-title":"Methods Mol Med"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib15","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.rdc.2014.12.005_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI42090","article-title":"Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis","volume":"121","author":"Li","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib18","doi-asserted-by":"crossref","first-page":"L585","DOI":"10.1152\/ajplung.00151.2001","article-title":"Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"282","author":"Zhao","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib19","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"WNT\/beta-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2014.12.005_bib21","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"WNT\/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0002-9440(10)64282-4","article-title":"Aberrant Wnt\/beta-catenin pathway activation in idiopathic pulmonary fibrosis","volume":"162","author":"Chilosi","year":"2003","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib23","first-page":"772","article-title":"WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis","volume":"119","author":"Konigshoff","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.11-0801","article-title":"Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study","volume":"142","author":"Theodore","year":"2012","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.rdc.2014.12.005_bib25","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2014.12.005_bib26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.rdc.2014.12.005_bib27","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.rdc.2014.12.005_bib28","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2014.12.005_bib29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"127","key":"10.1016\/j.rdc.2014.12.005_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.rdc.2014.12.005_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2013a consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semarthrit.2010.03.002","article-title":"Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence","volume":"40","author":"Christmann","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1164\/rccm.200808-1359OC","article-title":"Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring","volume":"179","author":"Savarino","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.rdc.2014.12.005_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard.2006.054866","article-title":"Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test","volume":"66","author":"Buch","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2014.12.005_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2014.12.005_bib37","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A\u00a0multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2014.12.005_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rdc.2014.12.005_bib40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"Simeon-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2014.12.005_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"Zamora","year":"2008","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.rdc.2014.12.005_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","article-title":"Experience with azathioprine in systemic sclerosis associated with interstitial lung disease","volume":"23","author":"Dheda","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib44","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2014.12.005_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","article-title":"Outcomes in systemic sclerosis-related lung disease after lung transplantation","volume":"95","author":"Sottile","year":"2013","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.rdc.2014.12.005_bib46","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.12.005_bib47","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","author":"Jordan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2014.12.005_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2014.12.005_bib49","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2014.12.005_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.rdc.2014.12.005_bib51","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A\u00a0one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2014.12.005_bib52","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2014.12.005_bib53","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.rdc.2014.12.005_bib54","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9790","key":"10.1016\/j.rdc.2014.12.005_bib55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.rdc.2014.12.005_bib56","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:53Z","timestamp":1760181293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X14001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0889857X14001264"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2014.12.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Lung Disease in Scleroderma","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2014.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}